Bysanti (milsaperidone) is an FDA-approved atypical antipsychotic indicated for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. As an oral therapy, Bysanti is designed to modulate key neurotransmitter pathways, particularly dopamine and serotonin receptor activity, which play a central role in psychosis and mood dysregulation.

Clinical development programs have demonstrated their efficacy in reducing core symptoms such as hallucinations, delusions, mood instability, and agitation, while maintaining a manageable safety and tolerability profile. With schizophrenia and bipolar I disorder representing significant chronic psychiatric conditions worldwide, Bysanti enters a highly competitive CNS market, making regulatory exclusivity tracking, patent lifecycle assessment, and future generic strategy evaluation critical for pharmaceutical intelligence teams.